Published in PLoS Med on March 01, 2006
Corruption of innate immunity by bacterial proteases. J Innate Immun (2009) 1.96
Group A streptococcus activates type I interferon production and MyD88-dependent signaling without involvement of TLR2, TLR4, and TLR9. J Biol Chem (2008) 1.38
Cathelicidin LL-37 in severe Streptococcus pyogenes soft tissue infections in humans. Infect Immun (2008) 1.21
Transcriptome analysis of murine macrophages in response to infection with Streptococcus pyogenes reveals an unusual activation program. Infect Immun (2007) 1.15
Bacterial phenotype variants in group B streptococcal toxic shock syndrome. Emerg Infect Dis (2009) 1.10
Streptolysin O and NAD-glycohydrolase prevent phagolysosome acidification and promote group A Streptococcus survival in macrophages. MBio (2014) 1.02
The ScpC protease of Streptococcus pyogenes affects the outcome of sepsis in a murine model. Infect Immun (2008) 1.02
Polymorphisms in regulator of protease B (RopB) alter disease phenotype and strain virulence of serotype M3 group A Streptococcus. J Infect Dis (2012) 1.02
Antibodies against a surface protein of Streptococcus pyogenes promote a pathological inflammatory response. PLoS Pathog (2008) 0.98
Postpartum group a Streptococcus sepsis and maternal immunology. Am J Reprod Immunol (2011) 0.98
SalY of the Streptococcus pyogenes lantibiotic locus is required for full virulence and intracellular survival in macrophages. Infect Immun (2007) 0.97
Gene repertoire evolution of Streptococcus pyogenes inferred from phylogenomic analysis with Streptococcus canis and Streptococcus dysgalactiae. PLoS One (2012) 0.95
Streptococcus pyogenes biofilm growth in vitro and in vivo and its role in colonization, virulence, and genetic exchange. J Infect Dis (2014) 0.94
Cytosolic Replication of Group A Streptococcus in Human Macrophages. MBio (2016) 0.92
Importance of Toll-like receptor 9 in host defense against M1T1 group A Streptococcus infections. J Innate Immun (2011) 0.86
The innate immune response elicited by Group A Streptococcus is highly variable among clinical isolates and correlates with the emm type. PLoS One (2014) 0.86
CD46 Contributes to the severity of group A streptococcal infection. Infect Immun (2008) 0.86
Intrauterine group A streptococcal infections are exacerbated by prostaglandin E2. J Immunol (2013) 0.85
HMGB1 in severe soft tissue infections caused by Streptococcus pyogenes. Front Cell Infect Microbiol (2014) 0.85
Protease-armed bacteria in the skin. Cell Tissue Res (2012) 0.84
Vitamin D and the human antimicrobial peptide LL-37 enhance group a streptococcus resistance to killing by human cells. MBio (2012) 0.83
Intracellular Streptococcus pyogenes in human macrophages display an altered gene expression profile. PLoS One (2012) 0.81
Adult zebrafish model of streptococcal infection. Curr Protoc Microbiol (2009) 0.81
SpyA, a C3-like ADP-ribosyltransferase, contributes to virulence in a mouse subcutaneous model of Streptococcus pyogenes infection. Infect Immun (2011) 0.81
Extracellular Histones Induce Chemokine Production in Whole Blood Ex Vivo and Leukocyte Recruitment In Vivo. PLoS Pathog (2015) 0.81
Differential secretomics of Streptococcus pyogenes reveals a novel peroxide regulator (PerR)-regulated extracellular virulence factor mitogen factor 3 (MF3). Mol Cell Proteomics (2011) 0.80
Insufficient Acidification of Autophagosomes Facilitates Group A Streptococcus Survival and Growth in Endothelial Cells. MBio (2015) 0.79
Fluorescence microscopy methods for determining the viability of bacteria in association with mammalian cells. J Vis Exp (2013) 0.78
A MyD88-JAK1-STAT1 complex directly induces SOCS-1 expression in macrophages infected with Group A Streptococcus. Cell Mol Immunol (2014) 0.78
The equine antimicrobial peptide eCATH1 is effective against the facultative intracellular pathogen Rhodococcus equi in mice. Antimicrob Agents Chemother (2013) 0.77
Bordetella parapertussis survives inside human macrophages in lipid raft-enriched phagosomes. Infect Immun (2014) 0.77
Dynamin inhibition interferes with inflammasome activation and cytokine gene expression in Streptococcus pyogenes-infected human macrophages. Clin Exp Immunol (2014) 0.77
The FasX Small Regulatory RNA Negatively Regulates the Expression of Two Fibronectin-Binding Proteins in Group A Streptococcus. J Bacteriol (2015) 0.76
Biofilm in group A streptococcal necrotizing soft tissue infections. JCI Insight (2016) 0.75
IL-2 Expression and T lymphocyte Phenotyping in Young Children Suffering from Upper Respiratory Tract Infection with Streptococcus Pyogenes. Int J Biomed Sci (2016) 0.75
Differential neutrophil responses to bacterial stimuli: Streptococcal strains are potent inducers of heparin-binding protein and resistin-release. Sci Rep (2016) 0.75
Autophagy defends cells against invading group A Streptococcus. Science (2004) 9.53
An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med (2002) 3.39
A conserved Streptococcus pyogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin. Microb Pathog (1993) 2.99
Inactivation of Streptococcus pyogenes extracellular cysteine protease significantly decreases mouse lethality of serotype M3 and M49 strains. J Clin Invest (1997) 2.94
Cleavage of interleukin 1 beta (IL-1 beta) precursor to produce active IL-1 beta by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc Natl Acad Sci U S A (1993) 2.92
Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis (1992) 2.78
Group A streptococci efficiently invade human respiratory epithelial cells. Proc Natl Acad Sci U S A (1994) 2.39
EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG. EMBO J (2001) 2.38
Effect of a bacterial pheromone peptide on host chemokine degradation in group A streptococcal necrotising soft-tissue infections. Lancet (2004) 2.25
Inverse relation between disease severity and expression of the streptococcal cysteine protease, SpeB, among clonal M1T1 isolates recovered from invasive group A streptococcal infection cases. Infect Immun (2000) 2.24
Extracellular cysteine protease produced by Streptococcus pyogenes participates in the pathogenesis of invasive skin infection and dissemination in mice. Infect Immun (1999) 2.04
Genetic inactivation of an extracellular cysteine protease (SpeB) expressed by Streptococcus pyogenes decreases resistance to phagocytosis and dissemination to organs. Infect Immun (1998) 2.00
Vaccination with streptococcal extracellular cysteine protease (interleukin-1 beta convertase) protects mice against challenge with heterologous group A streptococci. Microb Pathog (1994) 1.98
Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev (1995) 1.95
Intracellular reservoir of Streptococcus pyogenes in vivo: a possible explanation for recurrent pharyngotonsillitis. Laryngoscope (1997) 1.67
Effect of group A streptococcal cysteine protease on invasion of epithelial cells. Infect Immun (1998) 1.54
Role of macrophages in host resistance to group A streptococci. Infect Immun (2004) 1.49
Molecular mechanisms of adhesion, colonization, and invasion of group A streptococci. Ann Med (2002) 1.45
Superantigens - powerful modifiers of the immune system. Mol Med Today (2000) 1.43
Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease. J Infect Dis (1994) 1.42
The SpeB virulence factor of Streptococcus pyogenes, a multifunctional secreted and cell surface molecule with strepadhesin, laminin-binding and cysteine protease activity. Mol Microbiol (2001) 1.37
Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. Infect Immun (1999) 1.36
A secreted streptococcal cysteine protease can cleave a surface-expressed M1 protein and alter the immunoglobulin binding properties. Res Microbiol (1998) 1.36
Cytolysin-dependent evasion of lysosomal killing. Proc Natl Acad Sci U S A (2005) 1.35
The role played by the group A streptococcal negative regulator Nra on bacterial interactions with epithelial cells. Mol Microbiol (2001) 1.31
Streptococcus pyogenes expressing M and M-like surface proteins are phagocytosed but survive inside human neutrophils. Cell Microbiol (2003) 1.29
Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. Eur J Immunol (2000) 1.27
Proteolysis and its regulation at the surface of Streptococcus pyogenes. Mol Microbiol (2002) 1.25
Survival of Streptococcus pyogenes within host phagocytic cells: a pathogenic mechanism for persistence and systemic invasion. J Infect Dis (2003) 1.24
Evidence for superantigen involvement in severe group a streptococcal tissue infections. J Infect Dis (2001) 1.23
alpha2-Macroglobulin-proteinase complexes protect Streptococcus pyogenes from killing by the antimicrobial peptide LL-37. J Biol Chem (2004) 1.23
Streptococcal erythrogenic toxin B abrogates fibronectin-dependent internalization of Streptococcus pyogenes by cultured mammalian cells. Infect Immun (2000) 1.14
Absence of SpeB production in virulent large capsular forms of group A streptococcal strain 64. Infect Immun (2000) 1.13
Host cell caveolae act as an entry-port for group A streptococci. Cell Microbiol (2003) 1.13
Interactions with fibronectin attenuate the virulence of Streptococcus pyogenes. EMBO J (2004) 1.12
Selective modulation of superantigen-induced responses by streptococcal cysteine protease. J Infect Dis (2003) 1.12
Absence of a cysteine protease effect on bacterial virulence in two murine models of human invasive group A streptococcal infection. Infect Immun (2001) 1.06
Impact of the SpeB protease on binding of the complement regulatory proteins factor H and factor H-like protein 1 by Streptococcus pyogenes. Infect Immun (2005) 1.04
An intracellular sanctuary for Streptococcus pyogenes in human tonsillar epithelium--studies of asymptomatic carriers and in vitro cultured biopsies. Acta Otolaryngol (1997) 1.04
Intracellular penetration and survival of Streptococcus pyogenes in respiratory epithelial cells in vitro. Acta Otolaryngol (1995) 1.00
Trojan horse effect: phagocyte-mediated Streptococcus iniae infection of fish. Infect Immun (2003) 0.92
Role of CsrR, hyaluronic acid, and SpeB in the internalization of Streptococcus pyogenes M type 3 strain by epithelial cells. Infect Immun (2002) 0.87
Intracellular survival of persistent group A streptococci in cultured epithelial cells. Int J Med Microbiol (2004) 0.80
Identification of severe acute respiratory syndrome in Canada. N Engl J Med (2003) 14.29
Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med (2013) 11.85
Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol (2005) 9.76
The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet (2004) 9.37
Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med (2006) 7.01
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med (2002) 6.22
Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis (2007) 5.39
DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. Curr Biol (2006) 5.22
Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA (2013) 4.69
Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. Antimicrob Agents Chemother (2004) 4.46
DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat Med (2007) 4.35
Investigation of a nosocomial outbreak of severe acute respiratory syndrome (SARS) in Toronto, Canada. CMAJ (2003) 3.96
Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis (2009) 3.86
Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis (2006) 3.80
Self-terminating diffraction gates femtosecond X-ray nanocrystallography measurements. Nat Photonics (2012) 3.68
Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med (2005) 3.58
Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis (2010) 3.42
An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med (2002) 3.39
Phagocytosis-independent antimicrobial activity of mast cells by means of extracellular trap formation. Blood (2008) 3.32
Empirical validation of guidelines for the management of pharyngitis in children and adults. JAMA (2004) 3.14
Triple reassortant H3N2 influenza A viruses, Canada, 2005. Emerg Infect Dis (2006) 3.05
West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario. CMAJ (2003) 3.03
At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia. Clin Infect Dis (2008) 2.71
Evolutionary pathway to increased virulence and epidemic group A Streptococcus disease derived from 3,615 genome sequences. Proc Natl Acad Sci U S A (2014) 2.63
Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis (2005) 2.59
Laboratory characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: results of 5 years of National Surveillance, 1995-1999. J Infect Dis (2002) 2.57
Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis (2003) 2.54
M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell (2004) 2.46
Molecular complexity of successive bacterial epidemics deconvoluted by comparative pathogenomics. Proc Natl Acad Sci U S A (2010) 2.43
Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother (2003) 2.41
Time-resolved protein nanocrystallography using an X-ray free-electron laser. Opt Express (2012) 2.38
Reducing antimicrobial therapy for asymptomatic bacteriuria among noncatheterized inpatients: a proof-of-concept study. Clin Infect Dis (2014) 2.37
Genome-wide molecular dissection of serotype M3 group A Streptococcus strains causing two epidemics of invasive infections. Proc Natl Acad Sci U S A (2004) 2.32
Mutational analysis of the group A streptococcal operon encoding streptolysin S and its virulence role in invasive infection. Mol Microbiol (2005) 2.30
Genetic variability of human respiratory syncytial virus A strains circulating in Ontario: a novel genotype with a 72 nucleotide G gene duplication. PLoS One (2012) 2.21
Rise and persistence of global M1T1 clone of Streptococcus pyogenes. Emerg Infect Dis (2008) 2.14
SARS among critical care nurses, Toronto. Emerg Infect Dis (2004) 2.10
Host genetic variation affects resistance to infection with a highly pathogenic H5N1 influenza A virus in mice. J Virol (2009) 2.08
Healthcare-associated influenza in Canadian hospitals from 2006 to 2012. Infect Control Hosp Epidemiol (2014) 2.06
Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis (2005) 2.03
Invasive M1T1 group A Streptococcus undergoes a phase-shift in vivo to prevent proteolytic degradation of multiple virulence factors by SpeB. Mol Microbiol (2004) 1.99
Outcomes assessment of the surgical management of esophageal cancer in younger and older patients. Ann Thorac Surg (2012) 1.96
SARS in healthcare facilities, Toronto and Taiwan. Emerg Infect Dis (2004) 1.95
Severe group a streptococcal soft-tissue infections in Ontario: 1992-1996. Clin Infect Dis (2002) 1.93
Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience. Vaccine (2010) 1.91
Mosaic prophages with horizontally acquired genes account for the emergence and diversification of the globally disseminated M1T1 clone of Streptococcus pyogenes. J Bacteriol (2005) 1.90
Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood (2011) 1.87
Revisiting the pathogenesis of rheumatic fever and carditis. Nat Rev Cardiol (2013) 1.84
Risk of infection following a visit to the emergency department: a cohort study. CMAJ (2012) 1.83
New Delhi metallo-beta-lactamase, Ontario, Canada. Emerg Infect Dis (2011) 1.81
Phylogenetic analysis reveals a cryptic species Blastomyces gilchristii, sp. nov. within the human pathogenic fungus Blastomyces dermatitidis. PLoS One (2013) 1.79
Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis (2010) 1.78
Pneumococcal pneumonia: potential for diagnosis through a urinary metabolic profile. J Proteome Res (2009) 1.78
Trigger for group A streptococcal M1T1 invasive disease. FASEB J (2006) 1.77
Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis (2005) 1.75
Clostridium difficile infection in hospitals: a brewing storm. CMAJ (2004) 1.74
Experimental exposure to wood-smoke particles in healthy humans: effects on markers of inflammation, coagulation, and lipid peroxidation. Inhal Toxicol (2006) 1.74
Update on herpes zoster vaccination: a family practitioner's guide. Can Fam Physician (2011) 1.74
New Delhi metallo-β-lactamase-1: local acquisition in Ontario, Canada, and challenges in detection. CMAJ (2011) 1.73
Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob Agents Chemother (2007) 1.72
Alternative methods of estimating an incubation distribution: examples from severe acute respiratory syndrome. Epidemiology (2007) 1.70
Modulation of bacterial growth by tumor necrosis factor-alpha in vitro and in vivo. Am J Respir Crit Care Med (2003) 1.70
Active sites of thioredoxin reductases: why selenoproteins? Proc Natl Acad Sci U S A (2003) 1.69
Treatment of Barrett's esophagus with early neoplasia: a comparison of endoscopic therapy and esophagectomy. Gastrointest Endosc (2008) 1.69
Clinical and epidemiologic features of group a streptococcal pneumonia in Ontario, Canada. Arch Intern Med (2003) 1.67
Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis (2007) 1.66
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother (2011) 1.66
Risk factors for resistance to antimicrobial agents among nursing home residents. Am J Epidemiol (2003) 1.62
Modeling transmission of methicillin-resistant Staphylococcus aureus among patients admitted to a hospital. Infect Control Hosp Epidemiol (2005) 1.61
Use of a selective enrichment broth to recover Clostridium difficile from stool swabs stored under different conditions. J Clin Microbiol (2005) 1.61
Canadian guidelines for the management of acute exacerbations of chronic bronchitis: executive summary. Can Respir J (2003) 1.58
Guillain-Barré syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med (2006) 1.57
Volume-outcome relationship in surgery for esophageal malignancy: systematic review and meta-analysis 2000-2011. J Gastrointest Surg (2011) 1.57
The society of thoracic surgeons guidelines on the diagnosis and staging of patients with esophageal cancer. Ann Thorac Surg (2013) 1.56
Severe acute respiratory syndrome (SARS): a year in review. Annu Rev Med (2005) 1.55
Identification of a streptolysin S-associated gene cluster and its role in the pathogenesis of Streptococcus iniae disease. Infect Immun (2002) 1.52
Effect of multivitamin and mineral supplementation on episodes of infection in nursing home residents: a randomized, placebo-controlled study. J Am Geriatr Soc (2007) 1.52
Variations in emm type among group A streptococcal isolates causing invasive or noninvasive infections in a nationwide study. J Clin Microbiol (2005) 1.50
Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. CMAJ (2004) 1.50
High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada. Antimicrob Agents Chemother (2010) 1.50
Identification of a progenitor of the CTX-M-9 group of extended-spectrum beta-lactamases from Kluyvera georgiana isolated in Guyana. Antimicrob Agents Chemother (2005) 1.50
A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis (2005) 1.49
Use of, effectiveness of, and attitudes regarding influenza vaccine among house staff. Infect Control Hosp Epidemiol (2003) 1.48